A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
- PMID: 33597508
- PMCID: PMC7890067
- DOI: 10.1038/s41467-020-20496-3
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Erratum in
-
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4. Nat Commun. 2021. PMID: 33990587 Free PMC article.
Abstract
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.PLoS Genet. 2013;9(3):e1003173. doi: 10.1371/journal.pgen.1003173. Epub 2013 Mar 27. PLoS Genet. 2013. PMID: 23544012 Free PMC article.
-
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22351618 Free PMC article.
-
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Hum Mol Genet. 2011 Aug 15;20(16):3304-21. doi: 10.1093/hmg/ddr226. Epub 2011 May 18. Hum Mol Genet. 2011. PMID: 21593217 Free PMC article.
-
Common genetic variants and cancer risk in Mendelian cancer syndromes.Curr Opin Genet Dev. 2010 Jun;20(3):299-307. doi: 10.1016/j.gde.2010.03.010. Curr Opin Genet Dev. 2010. PMID: 20399636 Review.
-
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.Endocr Relat Cancer. 2016 Oct;23(10):T69-84. doi: 10.1530/ERC-16-0277. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528622 Review.
Cited by
-
Variable number tandem repeats (VNTRs) as modifiers of breast cancer risk in carriers of BRCA1 185delAG.Eur J Hum Genet. 2023 Feb;31(2):216-222. doi: 10.1038/s41431-022-01238-z. Epub 2022 Nov 25. Eur J Hum Genet. 2023. PMID: 36434258 Free PMC article.
-
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.Front Oncol. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515. eCollection 2022. Front Oncol. 2022. PMID: 35463374 Free PMC article.
-
Effect Modification between Genes and Environment and Parkinson's Disease Risk.Ann Neurol. 2022 Nov;92(5):715-724. doi: 10.1002/ana.26467. Epub 2022 Sep 24. Ann Neurol. 2022. PMID: 35913124 Free PMC article. Review.
-
TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.NPJ Breast Cancer. 2022 Jul 19;8(1):84. doi: 10.1038/s41523-022-00446-6. NPJ Breast Cancer. 2022. PMID: 35853889 Free PMC article. Review.
-
BRCA1 and BRCA2 Mutations in Polish Women with Ductal Carcinoma In Situ.Cancers (Basel). 2025 Feb 11;17(4):613. doi: 10.3390/cancers17040613. Cancers (Basel). 2025. PMID: 40002208 Free PMC article.
References
-
- Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. - PubMed
-
- Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int. J. Cancer. 1997;71:800–809. - PubMed
-
- Nelson HD, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 2014;160:255–266. - PubMed
-
- Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–2416. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA176785/CA/NCI NIH HHS/United States
- U01 CA176726/CA/NCI NIH HHS/United States
- G1000143/MRC_/Medical Research Council/United Kingdom
- U19 CA148112/CA/NCI NIH HHS/United States
- U01 CA098758/CA/NCI NIH HHS/United States
- U10 CA180868/CA/NCI NIH HHS/United States
- R01 CA050385/CA/NCI NIH HHS/United States
- UM1 CA164917/CA/NCI NIH HHS/United States
- U01 CA199277/CA/NCI NIH HHS/United States
- U01 CA179715/CA/NCI NIH HHS/United States
- R01 CA128931/CA/NCI NIH HHS/United States
- U54 CA156733/CA/NCI NIH HHS/United States
- C1275/A19187/CRUK_/Cancer Research UK/United Kingdom
- C8221/A19170/CRUK_/Cancer Research UK/United Kingdom
- UM1 CA164973/CA/NCI NIH HHS/United States
- RC4 CA153828/CA/NCI NIH HHS/United States
- R01 CA142996/CA/NCI NIH HHS/United States
- C1287/A10710/CRUK_/Cancer Research UK/United Kingdom
- P50 CA125183/CA/NCI NIH HHS/United States
- Z01 ES044005/ImNIH/Intramural NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- 14136/CRUK_/Cancer Research UK/United Kingdom
- UM1 CA164920/CA/NCI NIH HHS/United States
- MR/N003284/1/MRC_/Medical Research Council/United Kingdom
- 11174/CRUK_/Cancer Research UK/United Kingdom
- P30 CA168524/CA/NCI NIH HHS/United States
- U01 CA161032/CA/NCI NIH HHS/United States
- C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
- R01 CA097396/CA/NCI NIH HHS/United States
- UM1 CA176726/CA/NCI NIH HHS/United States
- UL1 TR002538/TR/NCATS NIH HHS/United States
- C1275/C22524/CRUK_/Cancer Research UK/United Kingdom
- C1287/A16563/CRUK_/Cancer Research UK/United Kingdom
- R01 CA058860/CA/NCI NIH HHS/United States
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- Z01 ES049033/ImNIH/Intramural NIH HHS/United States
- 20861/CRUK_/Cancer Research UK/United Kingdom
- U10 CA027469/CA/NCI NIH HHS/United States
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- K07 CA092044/CA/NCI NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- C490/A16561/CRUK_/Cancer Research UK/United Kingdom
- P50 CA058223/CA/NCI NIH HHS/United States
- R01 CA100374/CA/NCI NIH HHS/United States
- 1000143/MRC_/Medical Research Council/United Kingdom
- C490/A10124/CRUK_/Cancer Research UK/United Kingdom
- U01 CA116167/CA/NCI NIH HHS/United States
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- P30 CA008748/CA/NCI NIH HHS/United States
- R01 CA214545/CA/NCI NIH HHS/United States
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- P30 CA051008/CA/NCI NIH HHS/United States
- C570/A16491/CRUK_/Cancer Research UK/United Kingdom
- R01 CA116167/CA/NCI NIH HHS/United States
- R01 CA177150/CA/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- G0401527/MRC_/Medical Research Council/United Kingdom
- C1275/A11699/CRUK_/Cancer Research UK/United Kingdom
- R01 CA063464/CA/NCI NIH HHS/United States
- 26886/CRUK_/Cancer Research UK/United Kingdom
- U10 CA037517/CA/NCI NIH HHS/United States
- P20 GM130423/GM/NIGMS NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- MR/M012190/1/MRC_/Medical Research Council/United Kingdom
- R25 CA112486/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- 16563/CRUK_/Cancer Research UK/United Kingdom
- IS-BRC-1215-20007/DH_/Department of Health/United Kingdom
- U01 CA063464/CA/NCI NIH HHS/United States
- R01 CA077398/CA/NCI NIH HHS/United States
- R01 CA054281/CA/NCI NIH HHS/United States
- R01 CA132839/CA/NCI NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- U01 CA058860/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- C1275/A15956/CRUK_/Cancer Research UK/United Kingdom
- C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
- C1287/A11990/CRUK_/Cancer Research UK/United Kingdom
- UL1 TR001881/TR/NCATS NIH HHS/United States
- C8197/A16565/CRUK_/Cancer Research UK/United Kingdom
- 10118/CRUK_/Cancer Research UK/United Kingdom
- R01 CA192393/CA/NCI NIH HHS/United States
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- U10 CA180822/CA/NCI NIH HHS/United States
- R37 CA054281/CA/NCI NIH HHS/United States
- U01 CA164973/CA/NCI NIH HHS/United States
- R01 CA140286/CA/NCI NIH HHS/United States
- 23382/CRUK_/Cancer Research UK/United Kingdom
- P30 ES009089/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous